Our findings suggest that targeting the FOXO3a/miR-4259/LDHA pathway may serve as a new treatment for pancreatic cancer, especially in patients with a poor response to gemcitabine chemotherapy. Here, FOXO3 is linked to pancreatic neoplasm.